HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions
The levels of HDAC1 are expected to adapt to clinical adjuvant targeted therapy in most types of solid cancer.
Authors
- Ying Cai (ORCID: https://orcid.org/0000-0002-3801-7559)
- Rui Liu (ORCID: https://orcid.org/0009-0002-3689-4061)
- Jun Xie (ORCID: https://orcid.org/0000-0003-0074-2349)
- Dina Liu (ORCID: https://orcid.org/0000-0001-5456-0159)
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Translational Cancer Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/tcr-24-23
- Citations
- 6
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- Chongqing Postdoctoral Science Foundation
- Chongqing Medical University
- Chongqing Municipal Education Commission
- Centre Scientifique et Technique du Bâtiment